Abstract
Neutrophil elastase, a serine proteinase from the chymotrypsin family, has been the object of comprehensive experimental and theoretical studies to develop efficient human neutrophil elastase inhibitors. The serine protease has been linked to the pathology of a variety of inflammatory diseases, making it an attractive target for the development of anti-inflammatory compounds.
In this work, we have built a common binding model of the 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one derivatives into the human neutrophil elastase binding site. This was accomplished through a comparative conformational analysis (using OMEGA, HYPERCHEM, and MOPAC software) of 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one inhibitors followed by rigid and flexible molecular docking (by the FRED and GLIDE programs) into the target protein. We conclude that OMEGA software generates the most representative conformers to model the protein-ligand interactions.Keywords: Conformational analysis, Benzoxazinone derivative, Biologically active conformation, Human neutrophil elastase inhibitor, Molecular docking, serine proteinase, chymotrypsin family, anti-inflammatory compounds, 2-pyridin-3-yl-benzo[d][1, 3]oxazin-4-one derivatives, MOPAC software
Current Pharmaceutical Design
Title:Modeling of 2-Pyridin-3-yl-Benzo[d][1,3]Oxazin-4-one Derivatives by Several Conformational Searching Tools and Molecular Docking
Volume: 19 Issue: 12
Author(s): Mohammad Goodarzi, Alina Bora, Ana Borota, Simona Funar-Timofei, Sorin Avram and Yvan Vander Heyden
Affiliation:
Keywords: Conformational analysis, Benzoxazinone derivative, Biologically active conformation, Human neutrophil elastase inhibitor, Molecular docking, serine proteinase, chymotrypsin family, anti-inflammatory compounds, 2-pyridin-3-yl-benzo[d][1, 3]oxazin-4-one derivatives, MOPAC software
Abstract: Neutrophil elastase, a serine proteinase from the chymotrypsin family, has been the object of comprehensive experimental and theoretical studies to develop efficient human neutrophil elastase inhibitors. The serine protease has been linked to the pathology of a variety of inflammatory diseases, making it an attractive target for the development of anti-inflammatory compounds.
In this work, we have built a common binding model of the 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one derivatives into the human neutrophil elastase binding site. This was accomplished through a comparative conformational analysis (using OMEGA, HYPERCHEM, and MOPAC software) of 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one inhibitors followed by rigid and flexible molecular docking (by the FRED and GLIDE programs) into the target protein. We conclude that OMEGA software generates the most representative conformers to model the protein-ligand interactions.Export Options
About this article
Cite this article as:
Goodarzi Mohammad, Bora Alina, Borota Ana, Funar-Timofei Simona, Avram Sorin and Vander Heyden Yvan, Modeling of 2-Pyridin-3-yl-Benzo[d][1,3]Oxazin-4-one Derivatives by Several Conformational Searching Tools and Molecular Docking, Current Pharmaceutical Design 2013; 19 (12) . https://dx.doi.org/10.2174/1381612811319120007
DOI https://dx.doi.org/10.2174/1381612811319120007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design Endogenous BMP-4/ROS/COX-2 Mediated IPC and Resveratrol Alleviated Brain Damage
Current Pharmaceutical Design Natural Antiulcerogenic Agents: An Overview
Current Bioactive Compounds Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design Effect of Lipid Emulsion on the Improvement of Renal Damage in Colistin- Induced Nephrotoxicity
Current Drug Safety Recent Patents on Mesenchymal Stem Cell Mediated Therapy in Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Naturally Occurring NF-κB Inhibitors
Mini-Reviews in Medicinal Chemistry LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based Therapeutics
Current Pharmaceutical Design Nitric Oxide and its Role in Ischaemic Brain Injury
Current Molecular Medicine Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets Antioxidant and Antiinflammatory Activities of Curcumin on Diabetes Mellitus and its Complications
Current Pharmaceutical Design Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics
Current Organic Chemistry Phosphonic Esters and their Application of Protease Control
Current Pharmaceutical Design Molecular Hydrogen as a Neuroprotective Agent
Current Neuropharmacology The Atherosclerosis Time-Line and the Role of the Endothelium
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Effect of the Antioxidant Drug "U-74389G" on Oophoritis During Ischemia Reperfusion Injury in Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tetrahydrobiopterin: A Vascular Redox Target to Improve Endothelial Function
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Drug Targets Differentiation Potential of Mesenchymal Stem Cells Derived from Adipose Tissue vs Bone Marrow Toward Annulus Fibrosus Cells In vitro
Current Stem Cell Research & Therapy